Poster Session II: Quality of life, palliative & supportive care, ethics and health economics
Nausea and vomiting are the most common complaints for patients with haematological neoplasia during conditioning. The risk of hematopoiesis stem cell transplantation (HSCT) always cause people in anxiety and depression, which add patients' discomforts.
The aim of this study is to observe the effect of lupentixol melitracen combined with ondansetron on nausea and vomiting.
160 patients with hematological neoplasia in the state of complete remission were included in this study. The patients were randomly divided into control group and lupentixol melitracen group. For patients in control group, they received recommended-dose of ondansetron during conditioning each day. For patients in lupentixol melitracen group, they received lupentixol melitracen 10.5 mg combined with ondansetron each day. The incidence of nausea and vomiting was evaluated before, during and after chemotherapeutics infusion in the first day of conditioning.
Totally 158 patients, 78 in control group and 80 in lupentixol melitracen group could be evaluated. The difference of chemotherapy drug intensity in the two groups has no statistical significance (P > 0.05). The incidence of nausea before, during and immediately after chemotherapeutics infusion was respectively 5.2%, 72.5%, 60.6% in the control group and 1.6%, 53.3%, 45.5% in the lupentixol melitracen group, and the difference was significant between the two groups (P < 0.05). While the incidence of vomiting in the two groups has no significant difference (P > 0.05).
Flupentixol melitracen combined with ondansetron is more effective to prevent nausea than single ondansetron in patients during the first day of conditioning but no more effect on vomiting in our study.